For our purposes, it is noteworthy that somatic mutations in IDH1 and IDH2 are found in several cancers – principally acute myelogenous leukemia (AML) and glioblastoma [18–20], but also cholangiocarcinomas and chondrosarcomas – and have proven to be effective therapeutic targets [21]. This evidence concerns the gene IDH2 and acute myeloid leukemia.